Crinetics Stock Ratings Boosted Following Palsonify Approval
Crinetics Pharmaceuticals has received a positive stock rating from Oppenheimer and a price target increase to $62 from Baird following the approval of its drug Palsonify. These endorsements reflect strong confidence in the company's growth potential and the efficacy of its new treatment, suggesting a promising outlook for investors.
Crinetics Stock Ratings Boosted Following Palsonify Approval
Crinetics Pharmaceuticals has received a positive stock rating from Oppenheimer and a price target increase to $62 from Baird following the approval of its drug Palsonify. These endorsements reflect strong confidence in the company's growth potential and the efficacy of its new treatment, suggesting a promising outlook for investors.
Why World Pulse Now
Global Coverage
All major sources, one page
Emotional Lens
Feel the mood behind headlines
Trending Stories
Know what’s trending, globally
Read Less, Know More
Get summaries. Save time
Multi-Language
Switch languages to read your way
Save for Later
Your stories, stored for later
Live Stats
Our system has analyzed 4,210 articles worldwide
~175 per hour
581 trending stories shaping headlines
From breaking news to viral moments
Monitoring 198 trusted sources
Major outlets & specialized publications
Latest update an hour ago
Always fresh